Lighthouse Investment Partners LLC Lowers Stake in Qiagen (NYSE:QGEN)

Lighthouse Investment Partners LLC reduced its stake in shares of Qiagen (NYSE:QGENFree Report) by 72.4% in the fourth quarter, Holdings Channel reports. The firm owned 22,454 shares of the company’s stock after selling 58,775 shares during the period. Lighthouse Investment Partners LLC’s holdings in Qiagen were worth $975,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its holdings in Qiagen by 66.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock worth $31,000 after purchasing an additional 283 shares in the last quarter. Toronto Dominion Bank acquired a new position in shares of Qiagen during the third quarter valued at about $41,000. Lindbrook Capital LLC increased its holdings in shares of Qiagen by 21.6% during the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock valued at $58,000 after acquiring an additional 237 shares in the last quarter. Blue Trust Inc. increased its holdings in shares of Qiagen by 253.9% during the fourth quarter. Blue Trust Inc. now owns 3,974 shares of the company’s stock valued at $161,000 after acquiring an additional 2,851 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new position in shares of Qiagen during the fourth quarter valued at about $211,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Trading Up 0.1 %

Shares of NYSE:QGEN opened at $44.88 on Tuesday. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.70. The firm has a market capitalization of $10.24 billion, a price-to-earnings ratio of 30.09, a price-to-earnings-growth ratio of 3.70 and a beta of 0.42. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. The business’s 50 day moving average price is $42.73 and its 200-day moving average price is $43.60.

Qiagen (NYSE:QGENGet Free Report) last posted its quarterly earnings data on Monday, April 29th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The firm had revenue of $459.00 million during the quarter, compared to the consensus estimate of $453.91 million. During the same period in the prior year, the company earned $0.53 EPS. The firm’s revenue was down 5.4% compared to the same quarter last year. On average, equities research analysts forecast that Qiagen will post 2.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Morgan Stanley upgraded Qiagen from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $49.48 to $51.00 in a research report on Friday, February 16th. Stifel Nicolaus dropped their target price on Qiagen from $55.00 to $45.00 and set a “hold” rating on the stock in a research report on Wednesday, May 1st. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $50.95.

Get Our Latest Research Report on QGEN

Qiagen Company Profile

(Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Articles

Want to see what other hedge funds are holding QGEN? Visit to get the latest 13F filings and insider trades for Qiagen (NYSE:QGENFree Report).

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with's FREE daily email newsletter.